Could a common vitamin restore immunotherapy power after antibiotics?

NCT ID NCT07119996

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at whether taking vitamin B3 (a common dietary supplement) can stop antibiotics from weakening the immune system's ability to fight bladder cancer. The trial includes people with a certain type of bladder cancer who have recently taken antibiotics. They will receive a combination of chemotherapy, an immunotherapy drug called tislelizumab, and vitamin B3. The goal is to see if this approach is safe and can help shrink tumors before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vitamin B3 (nicotinic acid), tislelizumab, gemcitabine, cisplatin
What this could lead to: If it works, this could point toward a way to prevent antibiotics from reducing the effectiveness of immunotherapy in bladder cancer.
What could go wrong: This is a very small, early-phase trial with only 12 participants. The results may not apply to all patients, and the combination could cause side effects from the chemotherapy and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma neoplasm urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER

Contacts and locations

Locations

Sun-Yatsen Memorial Hospital
RECRUITING

Guangzhou, Guangdong, 510260, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.